Osimertinib, a highly potent small molecule inhibitor of epidermal growth factor receptor (EGFR), was used in the presence of an EGFR mutation as had been used previously in the successful treatment of lung cancer (Soria et al. 2018). Here, EGFR is linked to lung carcinoma.